

Allo HSCT for High Risk Hemoglobinopathies

NCT06872333

Status	RECRUITING
Phase	Phase 2
Sponsor	Masonic Cancer Center, University of Minnesota
Enrollment	62 participants

Key Eligibility Criteria

Inclusion (7)

- Sickle Cell Disease (SCD)
 - SCD Patients with a fully matched sibling donor (MSD) irrespective of the frequency or severity of symptoms MSD transplant can be considered. Parents/patient must be counseled as to the risks and benefits and provide their voluntary informed consent
 - Transfusion Dependent Alpha- or Beta- Thalassemia
 - Diamond Blackfan Anemia
 - Other Non-Malignant Hematologic Disorders
- ... and 2 more (see full listing online)

Exclusion (6)

- Pregnant, breastfeeding or intending to become pregnant during the study. Persons of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days of the start of treatment
 - HIV Positive
 - Active, uncontrolled infection - infection that is stable or improving after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections) will be permitted
 - Known allergy to any of the study components
 - Psychiatric illness/social situations that, in the judgement of the enrolling Investigator, would limit compliance with study requirements
- ... and 1 more (see full listing online)

Locations (1 total)

Masonic Cancer Center, Minneapolis, Minnesota, United States